Abstract
Background Evaluating vaccine effectiveness (VE) of a full vaccine series and booster doses against COVID-19 is important for health decision-making.
Methods We systematically searched papers that evaluated VE of SARS-CoV-2 vaccines on PubMed, Web of Science, Cochrane Library, Google Scholar, Embase, Scopus, and preprint servers (bioRxiv and medRxiv) published from November 26th, 2021 to June 27th, 2022 (for full doses and first booster), and to January 8th, 2023 (for the second booster). The pooled VE against Omicron-associated symptomatic or any infection as well as severe events are estimated in a meta-analysis framework.
Results From 2,552 citations identified, a total of 42 were included. The vaccination of the first booster provided stronger protection against Omicron than the full doses alone, shown by the VE estimates of 53.1% (95% CI: 48.0−57.8) vs. 28.6% (95% CI: 18.5−37.4) against infection and 82.5% (95% CI: 77.8−86.2) vs. 57.3% (95% CI: 48.5−64.7) against severe disease. The second booster offered strong protection among adults within 60 days of vaccination against infection (VE=53.1%, 95% CI: 48.0−57.8) and severe disease (VE=87.3% (95% CI: 75.5-93.4), comparable to the first booster with corresponding VE estimates of 59.9% against infection and 84.8% against severe disease. The VEs of the booster doses against severe disease among adults sustained beyond 60 days, 77.6% (95% CI: 69.4−83.6) for the first and 85.9% (95% CI: 80.3−89.9) for the second booster. The VE against infection was less sustainable regardless of dose type. Pure mRNA vaccines provided comparable protection to partial mRNA vaccines, but both provided higher protection than non-mRNA vaccination.
Conclusion One or two booster doses of current SARS-CoV-2 vaccines provide considerable protection against Omicron infection and substantial and sustainable protection against Omicron-induced severe clinical outcomes.
Funding US CDC U01 CK000670
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Researchers YY, IL and SS in this study were funded by US CDC U01 CK000670
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
